Advertisement


Yucai Wang, MD, PhD, on Richter Transformation of CLL: Findings on Combination Therapy With an Immune Checkpoint Inhibitor

2024 ASCO Annual Meeting

Advertisement

Yucai Wang, MD, PhD, of the Mayo Clinic, discusses the increased efficacy of combination therapy with pembrolizumab plus a BCR kinase inhibitor compared with pembrolizumab alone in patients with Richter transformation of chronic lymphocytic leukemia (CLL; Abstract 7050).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
So, Richter's transformation is a rare but devastating complication of chronic lymphocytic leukemia or small lymphocytic lymphoma. The prognosis of this disease is poor without established standard of care treatments. Our institution did a phase two clinical trial investigating the efficacy of pembrolizumab in this disease. Previously, we have reported preliminary efficacy results of this trial. So in the first nine patients with Richter's transformation, we observed a response rate of 44%. In this updated analysis, we report updated efficacy data of single-agent pembrolizumab and the combination therapy with pembrolizumab and a BCR inhibitor. So in this trial, patients were first treated with single-agent pembrolizumab every three weeks for up to 12 months. Patients who only have stable disease after three cycles of treatment or those who progress at any time during this single-agent treatment phase can add a inhibitor of the B-cell receptor, either with a BTK inhibitor or a PI3K inhibitor. So in this updated analysis, we enrolled a total of 26 patients, nine in the initial cohort, as reported a number of years earlier, and 17 in an expansion cohort. Looking at the patient and the disease baseline characteristics, this is consistent with what you would observe in this patient population. To highlight, most of the patients had unmutated IgHV and about 40% of the patients had TP53 alterations. This is a heavily pretreated population with a median of three lines of prior therapy, with up to 11 lines of therapy for CIL and five lines of therapy for Richter's transformation. Over half of the patients were previously exposed to BTK inhibitor ibrutinib already, and the massive majority of those patients actually had disease progression on this agent. So again, a high-risk patient population, difficult to treat. So in this trial, we observed that with single-agent pembrolizumab treatment, the objective response rate was 23%, or six out of 26 responses. It was two CR and 4 PRs. What's interesting is that for the 16 patients who went on to receive a doublet therapy with pembrolizumab either in combination with ibrutinib or idelalisib, we saw a high response rate of over 60%. So again, these are patients who progressed through pembrolizumab, and most of the patients have been previously exposed to ibrutinib, so this 60% response rate is very encouraging. In terms of survival outcomes, in a single-agent phase they observed the median progression-free survival was three months, and the median progression-free survival in the doublet therapy phase was about eight months. In total, the median overall survival is about one year, and the overall survival rate at two years is 27%. So again, in this heavily pretreated population with high-risk disease features, this doublet therapy certainly looks very encouraging in inducing a response and to maintain that. So these data do suggest that a PD-L1 blockade in combination with a BCR inhibitor is efficacious in treating Richter's transformation and it warrants further exploration. We do have another ongoing trial examining the combination of PD-L1 blockade in combination with a BTK inhibitor and the venetoclax in this patient population, and we look forward to sharing those results in the future.

Related Videos

Clifford A. Hudis, MD: A Message From ASCO’s CEO

Clifford A. Hudis, MD, of the American Society of Clinical Oncology (ASCO), talks about the 2024 Annual Meeting, and a focus on the compassionate side of cancer care.

Skin Cancer

Pauline Funchain, MD, and Caroline Robert, MD, PhD, on Melanoma: New Data on Encorafenib, Binimetinib, Ipilimumab, and Nivolumab

Pauline Funchain, MD, of Stanford University, and Caroline Robert, MD, PhD, of Gustave Roussy, discuss phase II findings showing that combining encorafenib and binimetinib followed by ipilimumab and nivolumab vs ipilimumab and nivolumab can improve progression-free survival in patients with BRAF-V600E/K-mutated melanoma characterized by high lactate dehydrogenase and liver metastases (Abstract LBA9503).

Multiple Myeloma

Suzanne Trudel, MD, on Multiple Myeloma: Results From the DREAMM-8 Study of Treatments After Relapse

Suzanne Trudel, MD, of Canada’s Princess Margaret Cancer Centre, discusses phase III findings showing that, in patients with relapsed or refractory multiple myeloma who had one or more prior lines of treatment, belantamab mafodotin-blmf plus pomalidomide and dexamethasone improved progression-free survival and showed a favorable overall survival trend compared with pomalidomide plus bortezomib and dexamethasone.

Multiple Myeloma

Thierry Facon, MD, on Multiple Myeloma: Results From the IMROZ Study on Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone

Thierry Facon, MD, of the University of Lille and Lille University Hospital, discusses phase III findings showing for the first time that isatuximab, an anti-CD38 monoclonal antibody, when given with the standard of care (bortezomib, lenalidomide, dexamethasone, or VRd) to patients with newly diagnosed multiple myeloma who are transplant-ineligible, may reduce the risk of disease progression or death by 40.4% vs VRd alone (Abstract 7500).

Prostate Cancer

Anthony M. Joshua, MBBS, PhD, on Low-Risk Prostate Cancer and Metformin: New Trial Data

Anthony M. Joshua, MBBS, PhD, of Princess Margaret Cancer Centre, discusses results from the MAST study, which explored the question of whether metformin could reduce disease progression in men with low-risk prostate cancer who are undergoing active surveillance (LBA5002).

Advertisement

Advertisement




Advertisement